Humate- P, a human clotting factor complex, isolated from the purified fraction of human fresh-frozen plasma and contains highly purified, lyophilized concentrate of Antihemophilic Factor/von Willebrand Factor complex (VWF) (Human), administered intravenously to treat hemophilia A and von Willebrand disease (VWD). It works by decreasing bleeding time, increasing the amount of clotting factor VIII, which helps to stop hemorrhage.
Humate-P Discount - Save Up To 75%** Off!
The free Pharmacy Humate-P Discount Card can save you up to 75%** off your prescription prices. All you have to do is print the and bring it to the pharmacy to receive the benefits of our drug discount program. This is not insurance and is not valid in combination with any government-sponsored drug plans.
Humate-P is primarily indicated for treatment and as a prophylactic factor of bleeding in adult patients with classical hemophilia (hemophilia A). Following intravenous administration, Humate-P leads to an increase in plasma clotting factor VIII activity leading to activation of factor X and ultimately to the formation of thrombin and fibrin. Humate-P is also used by adults and pediatric patients with VWD for clinical treatment of spontaneous and trauma-induced bleeding episodes and to control bleeding pre and post-surgical operation in patients with severe VWD. It is also beneficial in patients with mild to moderate VWD where use of desmopressin is inadequate. Humate-P may also be used for other conditions not mentioned in this article.
Your doctor will determine the Humate-P dosage depending on a number of factors such as weight, type and severity of hemorrhage, FVIII level, and presence of inhibitors. Stick to the Humate-P dose as directed by the doctor and never alter the dosage plan unless authorized by the doctor. Dosing recommendations for treatment of classical hemophilia is as follows:
- Life-threatening hemorrhage: Initially, 40-50 IU FVIII: C/kg, followed by 20-25 IU FVIII: C/kg TID for 1 week. Continue the same dose OD or BD for another 1 week to maintain the FVIII: C level at 30-50% of normal.
- Dose for treatment of hemorrhage episodes in VWD: Give 40-80 IU VWF: RCo per kg body weight every 8-12 hours. Dose should be adjusted based on extent and location of hemorrhage.
Humate-P should be administered with fresh sterilize syringes (do not reuse), and contact your doctor right away if you miss to administer a dose of Humate-P.
Humate-P Side Effects
Using Humate-P may have side effects that may differ from one person to the other. The acuteness of the side effects may be different from one patient to the other depending on the patient"s body ability to handle the effects of the drug. Stop using Humate-P and report severe side effects to your doctor immediately. Seek medical attention if any of the following symptoms become severe or bothersome:
- Abdominal upset
- Reactions at site of injection.
- Peripheral edema
- Tingling sensation.
Call your doctor immediately if the following serious side effects manifest:
- Allergic reactions
- Shortness of breath
- Swelling or tenderness.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.
Before taking Humate-P with other drugs, inform your doctor about any medical conditions or allergies that you may have. This is because using Humate-P with other drugs may affect how the drug works and delay the expected results. Some pharmaceutical agents may interfere with Humate-P and it is paramount to consult your doctor on any prescription, nonprescription medicines, herbal products, or dietary supplements you are taking before he/she initiates Humate-P therapy.
- However, there are no known specific drug-drug interactions with Humate-P at the moment but studies are ongoing to establish likelihood of any interactions. Do not start, stop, or alter the dosage of any medicines without approval from your doctor.